<DOC>
	<DOCNO>NCT02917239</DOCNO>
	<brief_summary>Overall survival multiple myeloma ( MM ) patient increase significantly due availability new drug . Moreover , since MM incurable disease , patient expose repeated line therapy different agent . It therefore increasingly important monitor long-term side-effects treatment . In present study focus ocular disorder . This observational study aim assess prevalence ocular disorder 100 patient treatment follow-up MM .</brief_summary>
	<brief_title>Prevalence Ocular Disorders Multiple Myeloma ( MM-OO-16 )</brief_title>
	<detailed_description>This observational study aim assess prevalence ocular disorder patient treatment follow-up MM . Study population Patients diagnose multiple myeloma treatment and/or follow-up treatment multiple myeloma . The study aim enroll 100 patient . Endpoints Primary endpoint : To determinate prevalence main characteristic ocular disorder patient treatment / previously treat Multiple Myeloma . Secondary endpoint : 1 . To evaluate relation kind treatment multiple myeloma development ocular disorder 2 . To evaluate relation patient 's characteristic comorbidities ( sex , age , smoking , hypertension , diabetes , autoimmune disease ) presence ocular disorder population patient . Study design Patients enrol study time start 3rd month treatment , regardless still treatment . Patients undergo ocular evaluation include visual acuity analysis , evaluation anterior ocular segment , fundus oculus analysis , ocular pressure measurement , Schirmer 's Test . If clinically require ophthalmologist , patient also undergo : - Optical computerized tomography - Fundus autofluorescence - Fluorescein angiography - Computerized visual field</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Age &gt; 18 year Diagnosis Multiple Myeloma Patients start active treatment Multiple Myeloma since least two month Patients active treatment relapsed/refractory multiple myeloma Patients followup previous active treatment multiple myeloma Bilateral blindness precede diagnosis multiple myeloma No signature inform consent Patients start active treatment Multiple Myeloma since less two month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>